Abstract

Giant cell tumor of bone (GCTB) is a rare benign primary tumor of the bone. Bisphosphonate therapy is curently used in GCTB because of its anti-osteoclastic effects. Denosumab is fully human monoclonal antibody that inhibit disease progression in metastatic GCTB. We summurized tree patients GCTB patients with lung metastasis. The patient were received between 12-18 months denosumab and remain without disease progression between 6-15 months after discontinuous of treatment. Due to the indolent nature of the tumor follow-up period may be short, however we thinks it is an important experience fort his condition